Medical Condition News

RSS

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

8 Dec 2009

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium S.p.A. today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the American Society of Hematology Conference (ASH) in New Orleans.

8 Dec 2009

ERSPC study shows PSA screening reduced prostate cancer deaths by 20%

The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported - up to 31%.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Calling his work "one of the most important findings in breast cancer and health disparities in the last decade," the American Association for Cancer Research (AACR) has named Charles M. Perou, Ph.D. the 2009 Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure-.

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Scientists attribute breast cancer decline to publicity surrounding WHI results

Between 2002 and 2003, American women experienced a 7 percent decline in breast cancer incidence, which scientists attribute to the publicity surrounding results of the Women's Health Initiative (WHI).

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Turmeric and pepper may play a role in preventing breast cancer

A new study finds that compounds derived from the spices turmeric and pepper could help prevent breast cancer by limiting the growth of stem cells, the small number of cells that fuel a tumor's growth.

8 Dec 2009

Long-chain omega-3 fatty acids can prevent colorectal cancer

Long-chain omega-3 fatty acids, primarily found in fish and seafood, may have a role in colorectal cancer prevention, according to results presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9, 2009, in Houston.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

U.S. cancer rates continue to decline in racial and ethnic populations

Good news in the fight against cancer! A new report from leading health and cancer organizations shows national cancer rates continue to decline.

8 Dec 2009

Animal study demonstrates how whole chromosome changes cause cancer

Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes -- called aneuploidy -- can cause cancer by eliminating tumor suppressor genes.

8 Dec 2009

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

BMI and waist circumference explain one half of all fatal and one quarter of all non-fatal cardiovascular disease in those overweight and obese in ten-year follow-up study

8 Dec 2009

Findings shed light on the genetic origins of diabetes

Pediatric researchers have found that a gene already implicated in the development of type 2 diabetes in adults also raises the risk of being overweight during childhood. The finding sheds light on the genetic origins of diabetes and may present an avenue for developing drugs to counteract the disease, which has been on the upswing in childhood and adolescence.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Selenium-based antioxidant compound reduces risk of colorectal cancer

Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel — called colorectal metachronous adenomas — in people who previously had colorectal polyps removed.

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

Medical Condition News

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

ERSPC study shows PSA screening reduced prostate cancer deaths by 20%

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Scientists attribute breast cancer decline to publicity surrounding WHI results

JAK2 inhibitor can control myelofibrosis, report researchers

Turmeric and pepper may play a role in preventing breast cancer

Long-chain omega-3 fatty acids can prevent colorectal cancer

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

U.S. cancer rates continue to decline in racial and ethnic populations

Animal study demonstrates how whole chromosome changes cause cancer

One half of fatal and one quarter of non-fatal CVD is linked to overweight and obesity, says new study

Findings shed light on the genetic origins of diabetes

Amgen announces results from first Phase 1/2 study of Nplate

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Selenium-based antioxidant compound reduces risk of colorectal cancer

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News